We found that anthracycline followed by taxane-based neoadjuvant chemotherapy combined with dual HER2-blockade resulted in a higher pCR rate when compared with single HER2-blockade in locally advanced HER2 breast cancer patients who need neoadjuvant treatment. This evidence concerns the gene ERBB2 and breast carcinoma.